Edesa Biotech, Inc. (EDSA)

Market Cap	51.54M +268.8%
Revenue (ttm)	n/a
Net Income	-10.44M
EPS	-1.37
Shares Out	8.89M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	180,117
Open	5.65
Previous Close	5.65
Day's Range	5.58 - 6.27
52-Week Range	0.72 - 20.32
Beta	1.07
Analysts	Strong Buy
Price Target	14.00 (+141.38%)
Earnings Date	May 14, 2026

About EDSA

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic allergic contact dermatitis. The company develops EB07,...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 17
• Stock Exchange: NASDAQ
• Ticker Symbol: EDSA
• Website: https://www.edesabiotech.com

Analyst Summary

According to one analyst, the rating for EDSA stock is "Strong Buy" and the 12-month stock price target is $14.0.

Price Target

$14.0

(141.38% upside)

Analyst Consensus: Strong Buy